Aprea Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed August 11, 2022, under Item 2.02 to announce financial results and an operational update for the second quarter ended June 30, 2022. The filing furnishes, but does not include in the provided text, the related August 11, 2022 press release as Exhibit 99.1.
Financial Metrics
- The provided filing text does not provide clear values for revenue, net income or loss, operating expenses, cash flow, cash and equivalents, margins, debt, liquidity, or cash runway.
- No balance sheet, income statement, or cash flow statement is included in the provided text.
Material Changes Versus Prior Period
The filing states that the company provided an operational update for the second quarter, but the provided text does not describe specific changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not include management guidance, forecasts, clinical or operating milestones, risk updates, contingencies, or unusual items. These details may be contained in Exhibit 99.1, which is not reproduced in the source content.
Important Facts to Verify
- Review Exhibit 99.1 for the complete second-quarter financial results and management commentary.
- Verify cash balances, quarterly cash use, debt, and expected liquidity runway.
- Confirm any clinical, regulatory, financing, or corporate milestones discussed in the press release.
- Note that the Item 2.02 information and Exhibit 99.1 were furnished and are not deemed filed for purposes of Exchange Act Section 18 liability unless expressly incorporated by reference.